- The Wall Street Journal•3 hours ago
Bristol-Myers Squibb Co. has passed on an option to acquire F-star Alpha Ltd. that it had gained through a $475 million agreement with the venture-backed drug company.
- Investor's Business Daily•4 hours ago
Bristol-Myers grabbed a pair of wins Friday after China approved its hepatitis C regimen and Europe blessed immuno-oncology drug Opdivo in head-and-neck cancer.
- Motley Fool•6 hours ago
If you're not buying Bristol-Myers because of last year's Opdivo trial failure, you ought to reconsider.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||55.37 - 56.33|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.15|
|Dividend & Yield||1.56 (2.95%)|
|1y Target Est||N/A|